Digipath
Home > Boards > US OTC > Biotechs >

Delcath Systems Inc. (DCTH)

DCTH RSS Feed
Add DCTH Price Alert      Hide Sticky   Hide Intro
Moderator: DesertEagle, Bond, TradedAhead
Search This Board: 
Last Post: 1/19/2019 6:46:26 PM - Followers: 531 - Board type: Free - Posts Today: 0

Web Site: Delcath Systems, Inc.
Stock and Financial Info: OTC Marketplace

About Delcath Systems (OTCQB:DCTH)
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Their proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe, their proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In April 2012, they obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has commenced a global phase 2 clinical trial in Europe to investigate Melphalan/HDS system for primary liver cancer and is initiating plans to evaluate intrahepatic cholangiocarcinoma.
 
Delcath Systems was formed in 1988 as a Pharmaceutical and Medical Device company focused on oncology. The company is registered in Delaware with offices in New York, New York and Manufacturing, Distribution, Research and Development facilities located in Queensbury, New York. The company currently has 10 patents in their US Intellectual Property portfolio according to the US Patent Office.
 
Subsidiaries of Delcath Systems include Delcath Holdings Limited (Ireland), Delcath Systems Limited (Ireland), Delcath Systems B.V. (Netherlands), Delcath Systems Gmbh (Germany) and Delcath Systems UK (United Kingdom).
 
Delcath Systems Securities
Delcath Systems securities originally came on the market on June 16, 2000 with an IPO offering of 1.2m shares priced at $6.00 per share. Securities were listed on both the NASDAQ and Boston Stock Exchange. The stock moved from the NASDAQ to the OTCQB on September 15, 2017 after the company Voluntarily Delisted it from NASDAQ and requested an Accelerated listing in the OTC marketplace.
 
The stock has been (reverse) split a total of 4 times. Twice while on the NASDAQ and twice since moving to the OTCQB.
 
The 1st split came on April 9, 2014 at a ratio of 1:16
The 2nd split came on July 21, 2016 at a ratio of 1:16
The 3rd split came on November 6, 2017 at a ratio of 1:350
The 4th split came on May 2, 2018 at a ratio of 1:500
 
Current Authorized Shares: 1.01 Billion
Common Shares Outstanding: 11,163,954
Dilutive Shares (Warrants) Outstanding: 66,260,000
Preferred Shares Outstanding: 101 (worth 3,607,142 Common Shares @ 0.28 SP)
 
Delcath Systems Clinical Trials
Declcath Systems currently has two clinical trials underway. The first is the FOCUS Trial and the second the ALIGN Trial.
 
The FOCUS Trial is designed to evaluate patients who have melanoma that has spread from the eye to the liver. All patients in the study will be treated with Melphalan/HDS for up to 6 treatments. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment. The FOCUS Trial has an estimated completion date of April 2020. For more info click here  
 
The ALIGN Trial will evaluate two groups of patients who have intrahepatic cholangiocarcinoma. Each group will receive induction treatment with Cisplatin and Gemcitabine per SOC for 4 treatment cycles. Following induction treatment patients will be randomize (1:1), to 2 arms of treatment. One group (50%) will rreceive high dose chemotherapy delivered specifically to the liver, while the other group (50%) will continue treatment with Cisplatin and Gemcitabine. Patient in each group will get repeating cycles of treatment until the cancer advances. All patients will be followed until death. This study will compare the overall survival (OS) in patients with intrahepatic cholangiocarcinoma. The ALIGN Trial has an estimated completion date of January 2023. For more info click here


Digipath
DCTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DCTH News: Current Report Filing (8-k) 01/18/2019 01:42:16 PM
DCTH News: Current Report Filing (8-k) 01/07/2019 02:09:05 PM
DCTH News: Current Report Filing (8-k) 01/03/2019 08:41:44 AM
DCTH News: Current Report Filing (8-k) 12/31/2018 07:50:44 AM
DCTH News: Current Report Filing (8-k) 12/28/2018 08:32:28 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#47371  Sticky Note New Year = New Moderators DesertEagle 01/12/19 08:37:39 AM
#47462   Our kings last paragraph summarized the tri topics Turntheship 01/19/19 06:46:26 PM
#47461   There are 3 reasons for a reverse split: SAMNOTSAMUEL 01/19/19 03:55:01 PM
#47460   when they asked for last RS vote in Bond 01/19/19 12:54:33 PM
#47459   That guessing was based on yearly revenue being Bond 01/19/19 12:50:04 PM
#47458   Best of luck with the guessing game. DesertEagle 01/19/19 12:39:23 PM
#47457   To the best of my knowledge, and I DesertEagle 01/19/19 12:25:17 PM
#47456   Reverse split is a topic more on point SAMNOTSAMUEL 01/19/19 11:11:06 AM
#47455   GG don't think it's a good swing trade Turntheship 01/18/19 11:04:37 PM
#47454   Are you sure they Want relisting on NASDAQ? RainyDayWriter 01/18/19 07:42:31 PM
#47453   If they want to go to Nasdaq they TheGreatGuy 01/18/19 07:12:55 PM
#47452   Indeed. 2K is a healthy-enough position as I RainyDayWriter 01/18/19 06:03:52 PM
#47451   I am happy with my current diet of SAMNOTSAMUEL 01/18/19 05:55:23 PM
#47449   Shorting would not matter much for a reverse SAMNOTSAMUEL 01/18/19 05:27:26 PM
#47448   Absolutely. And oftentimes, with shady companies, the company RainyDayWriter 01/18/19 05:18:10 PM
#47447   Ninety pct of rs I've followed shorted big time. Turntheship 01/18/19 05:12:48 PM
#47446   Yes OUR co moderator posted what page number Turntheship 01/18/19 05:09:42 PM
#47445   Imo, that's a great question. Whereas a RainyDayWriter 01/18/19 04:36:56 PM
#47444   GG, how would another RS help Delcath? DesertEagle 01/18/19 04:15:59 PM
#47443   TGIF... Don't forget it is Happy Hour at DesertEagle 01/18/19 04:08:07 PM
#47442   good job DE for bringing up the Section Bond 01/18/19 02:48:52 PM
#47441   Ni Hao everyone. Seems I have been proven DesertEagle 01/18/19 02:47:16 PM
#47440   New 8-K just out: Item 1.02. Termination of a RainyDayWriter 01/18/19 01:56:14 PM
#47439   I think you're correct regarding RS and ratio. . RainyDayWriter 01/18/19 09:15:24 AM
#47438   i think that we are heading to one TheGreatGuy 01/17/19 06:19:59 PM
#47432   My guess is they must be at 50-60% Bond 01/17/19 01:31:30 PM
#47431   Good up to date summary read james. Thanx. Turntheship 01/17/19 01:10:53 PM
#47430   I think enrollment complete is a distant second. Turntheship 01/17/19 01:03:42 PM
#47428   Comeback Time for Delcath Systems, Inc Bond 01/17/19 12:17:56 PM
#47427   2019 if no bankruptcy is about dilution, date SAMNOTSAMUEL 01/17/19 09:58:43 AM
#47426  Restored You forgot one: an out-of-court settlement. Big win. RainyDayWriter 01/17/19 05:59:20 AM
#47425   Sammy as you have said it's about dilution Turntheship 01/17/19 12:00:55 AM
#47424   Think from last 10q 850000 DOLLARS raised from Turntheship 01/16/19 11:53:12 PM
#47423   I am skeptical that there should be a SAMNOTSAMUEL 01/16/19 06:10:48 PM
#47422   If you paid attention to the dilution table Bond 01/16/19 05:57:10 PM
#47421   Thanks, everybody should be on board that annual SAMNOTSAMUEL 01/16/19 05:50:55 PM
#47420   SNS, fully agree with your observations. Problem is DesertEagle 01/16/19 05:46:35 PM
#47419   The more important figure is completed enrollment date, SAMNOTSAMUEL 01/16/19 05:29:12 PM
#47418   SNS, Delcath has moved away from "real" before. DesertEagle 01/16/19 05:09:58 PM
#47417   It hasn't recovered but with medac if legit Turntheship 01/16/19 04:29:28 PM
#47416   Wow just realized info content at top Turntheship 01/16/19 04:20:10 PM
#47414   I would be the last to believe the SAMNOTSAMUEL 01/16/19 09:04:07 AM
#47413   TTS, I would reserve judgement on the Delcath/medac DesertEagle 01/16/19 04:20:40 AM
#47412   L Bond 01/15/19 09:49:48 PM
#47411   That's always a possibility with this company. Turntheship 01/15/19 08:30:59 PM
#47410   Digest this: Even if they Say it's real, RainyDayWriter 01/15/19 08:25:56 PM
#47409   So when 10k comes out in 60 days Turntheship 01/15/19 08:23:41 PM
#47408   Your statement proved my point RainyDayWriter 01/15/19 07:08:44 PM
#47407   I know Heiner. . RainyDayWriter 01/15/19 07:07:05 PM
#47405   I only post valid info. RainyDayWriter 01/15/19 07:05:23 PM
#47399   Lol yeah seems like Medac is saying lot Bond 01/15/19 06:55:59 PM
PostSubject